primary biliary cirrhosis

(redirected from Cholestatic liver disease)
Also found in: Dictionary, Medical.

primary biliary cirrhosis

[¦Prīm·ə·rē ‚bil·ē·er·ē sə′rō·səs]
(medicine)
A slowly progressive disease primarily of middle-aged women, caused by an autoimmune destruction of bile ducts that begins as inflammation in and around larger intrahepatic bile ducts and eventually results in liver cell damage.
References in periodicals archive ?
The R&D Leadership Team will highlight a number of programs in Shire s research portfolio, as well as provide updates on several clinical programs in development, including SHP606 (lifitegrast) in Dry Eye Disease, SHP625 (LUM001) in Cholestatic Liver Disease, SHP626 (LUM002) for adults with Nonalcoholic Steatohepatitis (NASH), and SHP607 for the prevention of Retinopathy of Prematurity (ROP).
SAN FRANCISCO -- The SSRI sertraline improved pruritus from cholestatic liver disease in a small double-blind crossover study of 12 patients, Dr.
Patients with cholestatic liver disease may develop hepatotoxic injury from endogenous bile acids, resulting in progressive hepatic damage, hepatic failure, and, ultimately, death.
GKT137831 similarly prevented fibrosis in the BDLmodel, which mimics human cholestatic liver disease.
The R&D Leadership Team will highlight a number of programs in Shire's research portfolio, as well as provide updates on several clinical programs in development, including SHP606 (lifitegrast) in Dry Eye Disease, SHP625 (LUM001) in Cholestatic Liver Disease, SHP626 (LUM002) for adults with Nonalcoholic Steatohepatitis (NASH), and SHP607 for the prevention of Retinopathy of Prematurity (ROP).
Rare causes of cholestatic liver disease are also discussed, as well as systemic disorders and complications of this medical condition.
The chronic cholestatic liver disease has an unknown etiology, but it is associated with inflammatory bowel disease in up to 75% of patients.
A4250 decreases the re-absorption of bile acids and will thereby reduce the toxic levels of bile acids in the liver cells of patients with cholestatic liver disease.
These attractive potential treatments may offer new hope to patients with rare cholestatic liver disease and further contribute to Shire's future growth.
INDIGO is an open-label, Phase 2 clinical trial designed to evaluate the efficacy and safety of LUM001 for the treatment of cholestatic liver disease in patients with PFIC.
The second section covers the functional properties of nutrition and diseases of the gastrointestinal tract, such as the molecular basis of diseases, and causes and nutritional measures in chronic enteropathy, including the role of parenteral and enteral nutrition, stressed mucosa, and cholestatic liver disease.